Latest Stock Market News

Rate this item

(1 Vote)

Balkrishna Industries, incorporated in the year 1961, is a Large Cap company (having a market cap of Rs 37538.33 Crore) operating in Tyres sector.

Rate this item

(1 Vote)

As of 31-Dec-2022, promoters held 43.92 per cent stake in the company, while FIIs held 13.9 per cent and domestic institutional investors had 2.12 per cent.

Increasing taxation (insurance, MFs, trading) can roll back some of the household savings into asset classes like fixed deposits, real estate, and physical gold. Whether there is already enough financial awareness among the populace to appreciate the long-term benefits of insurance/MFs beyond tax savings is a moot question," ICICI Securities said.

Rate this item

(1 Vote)

"For the time being, the outlook is for either sideways trading in a narrow range or edging lower," although "the bottom looks quite firm," particularly around 27,300, he said.

Rate this item

(1 Vote)

Indian equities have been experiencing weak performance for a considerable period, leading to a decline of over 10% in the Nifty benchmark index from its 52-week high levels. In Nifty pack, 38 stockthe s have underperformed the index.

Rate this item

(1 Vote)

On the technical charts, the RSI of the stock stood at 42.47.

"We maintain our e-auction premium estimate for FY23 at 231%, and we reiterate our Buy rating on the stock with a target price of Rs 275 (5x EV/EBITDA). Coal India continues to be our top pick in the mining sector. Any hike in FSA will further add to the financial performance of the company," Motilal said.

Indian Hotels shares fall 1.35% as Nifty gains

Updated at : 2023-03-27 14:40:03

Rate this item

(1 Vote)

A total of 34,463 shares changed hands on the counter till time (IST).

Rate this item

(1 Vote)

As per Trendlyne data, the average target price of the stock estimate is Rs 663, which shows an upside potential of 45% from the current market prices. The consensus recommendation from one analyst for Isgec Heavy Engineering is a strong buy.

Lupin is a pharmaceutical company headquartered in Mumbai, India. While, it is the third-largest pharmaceutical company in the US by prescription. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.